

# GAZYVA Experience Sharing Meeting

Date: 13<sup>th</sup> August 2016 (Saturday)

Time: 16:00-19:00

Venue: The Westin Kuala Lumpur



Under the auspices of



ENGINEERED FOR SUPERIORITY

## MEETING AGENDA

Saturday, August 13

16:00-16:05	Welcome & Introduction <i>Dr Ng Soo Chin, Subang Jaya Medical Centre</i>
16:05-16:40	Who is the GAZYVA patient? <i>Professor Stephen Mulligan, Royal North Shore Hospital, Sydney</i>
16:40-17:00	Case Presentation 1 <i>Dr Lim Soo Min, Hospital Sultanah Aminah</i>
17:00-17:35	Practical points in managing patients on GAZYVA <i>Professor Stephen Mulligan, Royal North Shore Hospital, Sydney</i>
17:35-17:50	Tea Break
17:50-18:10	Case Presentation 2 <i>Dr Ahlam Naila, Hospital Tengku Ampuan Afzan</i>
18:10-18:35	What is MRD negativity? <i>Professor Stephen Mulligan, Royal North Shore Hospital, Sydney</i>
18:35-19:00	Workshop- Who is the GAZYVA patient? <i>Professor Stephen Mulligan, Royal North Shore Hospital, Sydney</i>

19:00 Dinner

Kindly RSVP by registering at the website <http://roche.cvent.com/d/svqmw9> before 5<sup>th</sup> Aug 2016  
For registration enquiries, please contact:  
Ms Ching Sook Ginn at tel: 03-76285686  
or email: [sook\\_ginn.ching@roche.com](mailto:sook_ginn.ching@roche.com)  
CPD points will be awarded



Professor Stephen Mulligan is Senior Staff Specialist Haematologist at Royal North Shore Hospital, Sydney, and also Adjunct Professor, School of Molecular Bioscience, Faculty of Science, University of Sydney, and Director of Laboratory Haematology, Laverty Pathology, Sydney. He is the Founder and President of the Chronic Lymphocytic Leukaemia Australian Research Consortium (CLLARC). Professor Mulligan trained in Clinical and Laboratory Haematology in Sydney. He is a member of the Royal Australasian College of Physicians (FRACP) and the Royal College of Pathologists of Australasia (FRCPA). He is a member of the RCPA Haematology Quality Assurance Committee. He completed his Ph.D. at the Centenary Institute, Sydney, and then undertook a post-doctoral Fellowship with Professor Daniel Catovsky in London working on CLL and B-cell lymphoproliferative diseases. After returning to Australia, he has practiced both Clinical and Laboratory Haematology and maintained an active ongoing clinical and research interest in CLL. Professor Mulligan initiated and developed the conduct of CLL clinical trials in Australia through the Australasian Leukaemia and Lymphoma Group (ALLG). He is a member of the ALLG Scientific Advisory Committee and Leader of the ALLG CLL Disease Group. He has conducted a number of CLL clinical trials in Australia, most recently a trial in elderly CLL. He is an invited Principal Investigator for a number of international clinical trials and a regular reviewer for Haematology journals.



Roche (Malaysia) Sdn. Bhd. (Co. No. 11792-H)  
Level 21, The Pinnacle  
Persiaran Lagoon, Bandar Sunway  
47500 Subang Jaya  
Selangor Darul Ehsan  
Tel: +603 76285600  
Fax: +603-76285756  
GAZ140716MYa